1.60
0.03 (1.91%)
| 前收盘价格 | 1.57 |
| 收盘价格 | 1.58 |
| 成交量 | 2,387,738 |
| 平均成交量 (3个月) | 916,055 |
| 市值 | 173,036,800 |
| 价格/销量 (P/S) | 4.75 |
| 股市价格/股市净资产 (P/B) | 0.800 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业利益率 (TTM) | -152.75% |
| 稀释每股收益 (EPS TTM) | -1.71 |
| 季度收入增长率 (YOY) | -47.60% |
| 总债务/股东权益 (D/E MRQ) | 1.67% |
| 流动比率 (MRQ) | 3.99 |
| 营业现金流 (OCF TTM) | -20.07 M |
| 杠杆自由现金流 (LFCF TTM) | -59.12 M |
| 资产报酬率 (ROA TTM) | -15.72% |
| 股东权益报酬率 (ROE TTM) | -84.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看跌 | 看跌 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | Aclaris Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 2.00 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 2.66% |
| 机构持股比例 | 82.36% |
| 52周波幅 | ||
| 中 | 15.00 (837.50%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Scotiabank | 07 Mar 2025 | 15.00 (837.50%) | 购买 | 1.83 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合